

Pembrolizumab KEYNOTE-158 - Cohort K

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-158 - Cohort K

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Tumour agnostic
 Therapeutic Indication: Patients with unresectable or metastatic dMMR/MSI-H solid tumours that have progressed following prior treatment and have no alternative treatment options
 Experimental Arm: Pembrolizumab
 Control Arm: Single arm cohort study



